The University of Birmingham and Acticor Biotech Announce the First Patient Treated in LIBERATE, First Clinical Trial Evaluating Glenzocimab for Heart Attacks

Regulatory News:

The University of Birmingham and Acticor Biotech (Paris:ALACT) are proud to announce the first patient treated in the LIBERATE clinical study to evaluate glenzocimab efficacy in myocardial infarction.

In 2022, the University of Birmingham and Acticor Biotech signed a partnership agreement to evaluate glenzocimab efficacy in myocardial infarction in a new clinical trial called LIBERATE.

Having obtained full regulatory approval in August 2023, two cutting-edge clinical research sites, namely the Queen Elizabeth Hospital in Birmingham and the Northern General Hospital in Sheffield, are involved in the study. The Queen Elizabeth Hospital in Birmingham opened to recruitment on 24^th January 2024. It is expected that the Northern General Hospital in Sheffield will also open to recruitment by the end of February 2024.

The LIBERATE study, a randomized, double-blind Phase 2b trial, will enrol over 200 patients diagnosed with ST-elevation myocardial infarction (STEMI) and scheduled for percutaneous coronary intervention. The primary objective of the study is to evaluate both the safety and efficacy of glenzocimab at a dosage of 1000 mg compared to a placebo, specifically focusing on the reduction of myocardial infarct size at Day 90 post-treatment.

Doctor Mark Thomas, Associate Professor of Cardiology at the University of Birmingham and Honorary Consultant Cardiologist, who designed the trial and led its development, said: “We are very happy to have started recruiting into the LIBERATE clinical trial. This is the first time worldwide that this class of medication has been investigated in patients with heart attacks, after showing great promise in patients with stroke. We are grateful to our patients for helping us in our mission to find new treatments that may help to reduce the damage done by heart attacks.”

Professor Robert Storey, Professor of Cardiology at the University of Sheffield and Honorary Consultant Cardiologist and Director of the Cardiovascular Research Unit at Northern General Hospital, said: “We are very pleased to now recruit patients in the LIBERATE clinical trial. This study is exploring the potential of glenzocimab in reducing the type of blood clotting responsible for heart damage during heart attacks. This exciting collaboration with University of Birmingham and Acticor Biotech holds the potential to bring significant benefit to people suffering from a heart attack.”